SAKAR2023-04-012023-06-30 SAKAR2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member SAKAR2023-06-30 SAKAR2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SAKAR NOTLISTED Sakar Healthcare Limited Equity 2023-04-01 2024-03-31 2023-08-14 2023-08-07 INR Lakhs First quarter 14:00:00 14:50:00 2023-08-14 2023-08-14 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Consolidated 389888000.00 15208000.00 405096000.00 202624000.00 0.00 9083000.00 53649000.00 20773000.00 45187000.00 34274000.00 365590000.00 39506000.00 0.00 39506000.00 6623000.00 4480000.00 11103000.00 0.00 28403000.00 0.00 0.00 0.00 0.00 28403000.00 -532000.00 27871000.00 0.00 0.00 190400000.00 10 1.46 1.46 0.00 0.00 1.46 1.46 1. The Company is operating only in one segment. Hence segment reporting is not given. 2. The consolidated Unaudited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited. 3. The Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 “Interim Financial Reporting” as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. 4. Provision for taxation/deferred taxation, if any, will be made at the year end. 5. Figures, wherever required, are regrouped / rearranged. 6. The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 14th August, 2023 Figures, wherever required, are regrouped / rearranged other expenses 34274000.00 Re-measurement gains/(losses) on defined benefit plans -737000.00 -737000.00 -205000.00 0.00